Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine June 2006, 47 (6) 11a-12a;
  • Article
  • Info & Metrics
  • PDF
Loading

Mothersill and Seymour look at the promise of targeted radiotherapy and the evolving meaning and understanding of “bystander effects” as reported in an original article in this issue.
Page 899

Larson and Schwartz preview an article in this issue on the use of 18F-FDG PET in clinical trials and address the growing potential for PET as a biomarker to assess treatment response.
Page 901

Chen and colleagues compare the abilities of 18F-FDOPA and 18F-FDG as PET tracers in the assessment of amino acid and glucose metabolism in primary, recurrent, and metastatic brain tumors.
Page 904

Reardon and colleagues report on the dosimetry, pharmocokinetics, toxicity, and antitumor activity of a human IgG2/mouse chimeric monoclonal antibody administered directly into the surgical resection cavity in patients with malignant glioma.
Page 912

Figure

Catafau and colleagues describe quantification methods for a novel 123I-labeled SPECT ligand for the 5HT2A receptor and discuss the utility of the resulting simple protocol, which avoids arterial blood sampling and serial scanning over time.
Page 919

Catafau and colleagues expand on the study reported in the previous article, assessing the specificity of tracer-to-receptor binding, the relationship between ketanserin plasma concentrations and tracer displacement, and the suitability of the cerebellum as a reference region for quantification.
Page 929

Figure

Picchio and colleagues compare the diagnostic accuracies of contrast-enhanced CT and 11C-choline PET for staging of urothelial bladder cancer, with special attention to ability to pinpoint lymph node metastases.
Page 938

de Geus-Oei and colleagues report on the use of noninvasive image-derived input functions as an accurate, simple, and clinically viable alternative to arterial blood sampling in 18F-FDG PET evaluation of chemotherapeutic response.
Page 945

Jacene and colleagues evaluate the effects of pegfilgrastim, a long-acting granulocyte colony–stimulating factor, on biodistribution of 18F-FDG in a rat model and in patients with breast cancer and discuss the significance for 18F-FDG PET evaluation of tumor response.
Page 950

Belhocine and colleagues provide a comprehensive educational review and literature survey on the role of nuclear medicine techniques in the detection, staging, and restaging of malignant melanoma.
Page 957

Reinartz and colleagues describe the development of a procedure designed to automatically analyze ventilation/perfusion lung scans for match and mismatch defects, an approach that would improve SPECT accuracy and efficiency in identifying pulmonary embolisms.
Page 968

Kreissl and colleagues noninvasively determine parameters of cardiovascular function in mice by high-temporal-resolution imaging with a dedicated small-animal PET system, a technique with promise for monitoring change in response to pharmacologic intervention.…Page 974

Figure

Askoxylakis and colleagues conduct binding and biodistribution studies in mice to assess the potential of a 125I-labeled peptide as a candidate for the development of a neuroblastoma-specific vector to be used for drug targeting or radiopeptide-based diagnosis and therapy.
Page 981

Yuan and colleagues evaluate the recently developed tracer 64Cu-ATSM as a hypoxia PET marker in a rat model and compare the results with those from a well-established hypoxia marker.
Page 989

Fueger and colleagues report on the effects of variations in dietary conditions, mode of anesthesia, and ambient temperature on the biodistribution of 18F-FDG in mice undergoing small-animal PET imaging.
Page 999

Boyd and colleagues investigate the significance of indirect effects in targeted radionuclide treatment by performing a comparative assessment of biologic bystander effects resulting from external beam γ-radiation and those resulting from exposure to 3 radiohaloanalogs of MIBG.
Page 1007

Figure

Iozzo and colleagues determine in a swine model whether 18F-FDG can be used in simultaneous estimation of whole-body glucose turnover and production during the fasting and hyperinsulinemic states, facilitating correlation of systemic glucose metabolism with regional 18F-FDG PET.
Page 1016

Figure

Reilly and colleagues evaluate the pharmacokinetics, tissue distribution, radiation dosimetry, and toxicology of human epidermal growth factor and 111In-DTPA in mice and rabbits and discuss the implications for radiotherapeutic applications in growth factor receptor–positive breast cancer.
Page 1023

Lipowska and colleagues report on mouse and human biodistribution studies of a novel 99mTc-labeled tricarbonyl complex and outline its potential advantages as a clinical renal radiopharmaceutical.
Page 1032

Figure

Rowland and colleagues use small-animal PET imaging to assess the characteristics and PET radiotracer potential of 2 new 76Br-radiolabeled compounds with high affinity and selectivity for the σ2-receptor.
Page 1041

Figure

Neti and Howell determine the distribution of radiopharmaceutical activity per cell in a cell population and discuss the implications of log normal distribution of cellular radioactivity for predicting biologic response.
Page 1049

Shankar and colleagues present consensus guidelines for the acquisition and analysis of 18F-FDG PET scans of patients participating in NCI-sponsored diagnostic and therapeutic clinical trials.
Page 1059

ON THE COVER

From left to right and top to bottom, these images show cells with 0, 1, 3, 5, 7, and more than 9 α-particle tracks. The number of tracks in a given cell is directly proportional to the cumulated activity, which, in turn, is directly proportional to cellular activity. Therefore, the distribution of tracks per cell can also be used to describe the distribution of activity per cell. Theoretic calculations have indicated that a log normal distribution of radioactivity, as was found within this cell population, can profoundly affect modeling of the biologic response of the population.

Figure

SEE PAGE 1052

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 47 (6)
Journal of Nuclear Medicine
Vol. 47, Issue 6
June 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jun 2006, 47 (6) 11a-12a;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jun 2006, 47 (6) 11a-12a;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Targeted Radiotherapy: Is the “Holy Grail” in Sight?
  • 18F-FDG PET as a Candidate for “Qualified Biomarker”: Functional Assessment of Treatment Response in Oncology
  • 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy
  • Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
  • Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 1—Pseudoequilibrium Interval and Quantification Methods
  • Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 2—Ketanserin Displacement
  • Value of 11C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings
  • Comparison of Image-Derived and Arterial Input Functions for Estimating the Rate of Glucose Metabolism in Therapy-Monitoring 18F-FDG PET Studies
  • Effects of Pegfilgrastim on Normal Biodistribution of 18F-FDG: Preclinical and Clinical Studies
  • Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
  • SPECT Imaging in the Diagnosis of Pulmonary Embolism: Automated Detection of Match and Mismatch Defects by Means of Image-Processing Techniques
  • Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells
  • Intertumoral Differences in Hypoxia Selectivity of the PET Imaging Agent 64Cu(II)-Diacetyl-Bis(N4-Methylthiosemicarbazone)
  • Impact of Animal Handling on the Results of 18F-FDG PET Studies in Mice
  • Radiation-Induced Biologic Bystander Effect Elicited In Vitro by Targeted Radiopharmaceuticals Labeled with α-, β-, and Auger Electron–Emitting Radionuclides
  • 18F-FDG Assessment of Glucose Disposal and Production Rates During Fasting and Insulin Stimulation: A Validation Study
  • Preclinical Pharmacokinetic, Biodistribution, Toxicology, and Dosimetry Studies of 111In-DTPA-Human Epidermal Growth Factor: An Auger Electron–Emitting Radiotherapeutic Agent for Epidermal Growth Factor Receptor–Positive Breast Cancer
  • First Evaluation of a 99mTc-Tricarbonyl Complex, 99mTc(CO)3(LAN), as a New Renal Radiopharmaceutical in Humans
  • Synthesis and In Vivo Evaluation of 2 High-Affinity 76Br-Labeled σ2-Receptor Ligands
  • Log Normal Distribution of Cellular Uptake of Radioactivity: Implications for Biologic Responses to Radiopharmaceuticals
  • Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire